AMPK Activation

An innovative treatment for lifestyle and age-related diseases

Scientific concept

The global increase in obesity and an aging population promote type 2 diabetes, cardiovascular disease, fatty liver/NASH, chronic kidney disease, inflammatory conditions and certain cancers

“Pharmacological activation of AMPK mimics exercise & caloric restriction – mitigates multiple diseases associated with a sedentary lifestyle and aging

R&D

Betagenon explores innovative pharmacological activation of AMPK to develop novel and safe therapies

READ MORE

About AMPK

A key sensor & regulator of energy charge – Activated by Exercise & Caloric restriction

READ MORE

0304

Our lead AMPK activator mimics the multiple beneficial health effects of exercise and caloric restriction

READ MORE

News & events

Keep up to date with the latest news and findings

READ MORE

What we do

Betagenon is a clinical stage company that develops its proprietary first in class AMPK activators as novel innovative treatments for major diseases to reach commercial deals with relevant financial benefits

 

READ MORE

Betagenon is financed by private Investors:

Partnering

Betagenon is now actively seeking partners for the further clinical development AMPK activator O304 and of novel AMPK activator compounds

READ MORE